NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
| Condition(s) | Pancreatic Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities. |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1. * Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma. * Have metastatic disease * Must not have received prior systemic treatment for pancreatic cancer. * Have measurable disease based on RECIST 1.1. * Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures. * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. * For both Women and Men, must use acceptable form of birth control while on study. * Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and inst |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Locations | Baltimore, Maryland, United States |
| Start date | 2025-09-04 |
| NCT ID | NCT06941857 |
| Official listing | https://clinicaltrials.gov/study/NCT06941857 |